These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 18178863

  • 21. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 22. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.
    Knight JS, Subramanian V, O'Dell AA, Yalavarthi S, Zhao W, Smith CK, Hodgin JB, Thompson PR, Kaplan MJ.
    Ann Rheum Dis; 2015 Dec; 74(12):2199-206. PubMed ID: 25104775
    [Abstract] [Full Text] [Related]

  • 23. A novel antifolate, MX-68, inhibits the development of autoimmune disease in MRL/lpr mice.
    Mihara M, Takagi N, Urakawa K, Moriya Y, Takeda Y.
    Int Arch Allergy Immunol; 1997 Aug; 113(4):454-9. PubMed ID: 9250591
    [Abstract] [Full Text] [Related]

  • 24. CR1/CR2 deficiency alters IgG3 autoantibody production and IgA glomerular deposition in the MRL/lpr model of SLE.
    Boackle SA, Culhane KK, Brown JM, Haas M, Bao L, Quigg RJ, Holers VM.
    Autoimmunity; 2004 Mar; 37(2):111-23. PubMed ID: 15293881
    [Abstract] [Full Text] [Related]

  • 25. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
    Jiang C, Zhao ML, Scearce RM, Diaz M.
    Arthritis Rheum; 2011 Apr; 63(4):1086-96. PubMed ID: 21225690
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Expression of natural autoantibodies in MRL-lpr mice protects from lupus nephritis and improves survival.
    Mannoor K, Matejuk A, Xu Y, Beardall M, Chen C.
    J Immunol; 2012 Apr 15; 188(8):3628-38. PubMed ID: 22407922
    [Abstract] [Full Text] [Related]

  • 30. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.
    Arthritis Res Ther; 2016 Oct 22; 18(1):243. PubMed ID: 27770825
    [Abstract] [Full Text] [Related]

  • 31. Anti-C1q autoantibodies in murine lupus nephritis.
    Trouw LA, Seelen MA, Visseren R, Duijs JM, Benediktsson H, de Heer E, Roos A, van Kooten C, Daha MR.
    Clin Exp Immunol; 2004 Jan 22; 135(1):41-8. PubMed ID: 14678263
    [Abstract] [Full Text] [Related]

  • 32. Autoantibody responses and pathology regulated by B7-1 and B7-2 costimulation in MRL/lpr lupus.
    Liang B, Kashgarian MJ, Sharpe AH, Mamula MJ.
    J Immunol; 2000 Sep 15; 165(6):3436-43. PubMed ID: 10975864
    [Abstract] [Full Text] [Related]

  • 33. CSF-1R inhibition attenuates renal and neuropsychiatric disease in murine lupus.
    Chalmers SA, Wen J, Shum J, Doerner J, Herlitz L, Putterman C.
    Clin Immunol; 2017 Dec 15; 185():100-108. PubMed ID: 27570219
    [Abstract] [Full Text] [Related]

  • 34. Upregulation of FoxO3a expression through PI3K/Akt pathway attenuates the progression of lupus nephritis in MRL/lpr mice.
    Zhao C, Gu Y, Chen L, Su X.
    Int Immunopharmacol; 2020 Dec 15; 89(Pt A):107027. PubMed ID: 33039957
    [Abstract] [Full Text] [Related]

  • 35. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
    Pérez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlöndorff D, Luckow B.
    J Am Soc Nephrol; 2005 Dec 15; 16(12):3592-601. PubMed ID: 16267157
    [Abstract] [Full Text] [Related]

  • 36. Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis.
    Alexander JJ, Jacob A, Bao L, Macdonald RL, Quigg RJ.
    J Immunol; 2005 Dec 15; 175(12):8312-9. PubMed ID: 16339572
    [Abstract] [Full Text] [Related]

  • 37. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice.
    Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H.
    BMC Nephrol; 2019 Nov 21; 20(1):424. PubMed ID: 31752725
    [Abstract] [Full Text] [Related]

  • 38. Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms.
    Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC.
    Am J Pathol; 2007 Apr 21; 170(4):1258-66. PubMed ID: 17392165
    [Abstract] [Full Text] [Related]

  • 39. Absence of functional alternative complement pathway alleviates lupus cerebritis.
    Alexander JJ, Jacob A, Vezina P, Sekine H, Gilkeson GS, Quigg RJ.
    Eur J Immunol; 2007 Jun 21; 37(6):1691-701. PubMed ID: 17523212
    [Abstract] [Full Text] [Related]

  • 40. IgG4 Autoantibodies Attenuate Systemic Lupus Erythematosus Progression by Suppressing Complement Consumption and Inflammatory Cytokine Production.
    Pan Q, Xiao H, Shi L, He Y, Cai J, Wu J, Li A, Ye L, Yang C, Liu HF.
    Front Immunol; 2020 Jun 21; 11():1047. PubMed ID: 32625200
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.